Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Feb 04, 2023 1:42pm
174 Views
Post# 35266903

RE:Until March...

RE:Until March...jd, "Knowing Dr. Deborah Rathjen's very careful use of words with respect to both what is said and not said, it wouldn't surprise me that when she says that Bioasis's "remaining cash reserves will allow it to continue operations only until approximately March 2023," that she means precisely that."

What jd doesn't say is that BTI's news release also said:


"As a result, Bioasis does not currently expect to receive the expense reimbursement payment or the final instalment of the Midatech bridge loan unless and until Midatech is able to secure additional funding." 

Midatech had previously forecast that it only had enough cash until March. It is in a very tight financial position and it has only been nine business days since the 'no' vote concerning the deal with BTI. It is urgently seeking a path forward; but hasn't had much time to respond yet. Don't be surprised if Midatech announces a path forward financially in the very near term as it urgently seeks to address its situation. The market for small caps has improved significantly since the BTI deal was put together, Midatech shareholders voted down the BTI deal, and Midatech's stock price has been holding its own since the 'no' vote.

BTI is urgently assessing its own options. Given BTI's debt situation, and the need for a cash runway time will tell what happens. This is not a pretty situation.

On other matters, I can't find a replay to verifty but I believe Rathjen said J&J extended, and expanded the collaboration and made a small milestone payment.
 
<< Previous
Bullboard Posts
Next >>